NRx Pharmaceuticals has reported the latest positive safety data from the Phase III ACTIV-3b Critical Care trial of its experimental product, Zyesami (aviptadil) for Covid-19.

Sponsored by the National Institutes of Health, the randomised, placebo-controlled ACTIV-3b trial is analysing Zyesami and remdesivir (Veklury) as monotherapy and in combination in hospitalised Covid-19 patients with acute respiratory failure.

It enrolled subjects who need high-flow supplemental oxygen delivered by nasal cannula, mechanical ventilation or extracorporeal membrane oxygenation.

The Independent Data Safety Monitoring Board (DSMB) found no new safety concerns during its second scheduled analysis reviewing 232 subjects in the trial.

It also recommended the continuation of enrolment in the trial to target more than 600 subjects.

NRx Pharmaceuticals chairman and CEO professor Jonathan Javitt said: “With this second independent safety analysis in the ACTIV-3b trial, the safety database on Zyesami has grown to more than 500 patients across our various clinical trials and expanded access programmes.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“So far, there have been no reports of unexpected, drug-related serious adverse events.”

ACTIV-3b is one among the three trials of Zyesami progressing in severe or critical Covid-19 patients.

Zyesami for Covid-19 patients received fast-track status from the US Food and Drug Administration (FDA) earlier.

It is a synthetic form of vasoactive intestinal polypeptide and attaches especially to the alveolar type II cell in the lung air sac.

Prior to this, NRx reported top-line results from a study where Zyesami improved survival outcomes at one year in highly comorbid Covid-19 patients.

This trial was carried out between June and September 2020 at a tertiary care hospital that involved critical Covid-19 patients whose comorbidity level excluded them from the randomised Phase IIb/III clinical trial of Zyesami.